Literature DB >> 15607670

Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation.

Murali M Chakinala1, Jon Ritter, Brian F Gage, John P Lynch, Aviva Aloush, G Alexander Patterson, Elbert P Trulock.   

Abstract

BACKGROUND: Better understanding of the timing and pattern of surveillance bronchoscopy findings after lung transplantation could influence the timing and frequency of surveillance bronchoscopy. We present our surveillance bronchoscopy experience and test the hypothesis that patients not encountering early acute rejection or lymphocytic bronchitis/bronchiolitis are less likely to have subsequent occult occurrences in the 1st year after lung transplantation.
METHODS: We conducted a retrospective study of 204 patients who underword transplantation between 1996 and 2000. Based on contemporary biopsy-specimen grading in the first 100 days, we formed 2 groups: No Early Rejection and Early Rejection. We compared subsequent yields of surveillance bronchoscopy and the incidence of acute rejection or of lymphocytic bronchitis/bronchiolitis.
RESULTS: We reviewed 645 biopsies taken from 204 recipients during the first 100 days to classify patients into a No Early Rejection Group (n=67) or an Early Rejection Group (n=137). Yield of surveillance bronchoscopy for acute rejection or lymphocytic bronchitis/bronchiolitis was 31% with the greatest yield during the first 30 days (45%), and then decreasing to 26% (p <0.001). After Day 100, 71% of occult acute rejection episodes involved minimal (A1) lesions. Yield of surveillance bronchoscopy after Day 100 was 20% in the No Early Rejection Group and was 27% in the Early Rejection Group (p=0.22). Incidence of acute rejection or lymphocytic bronchitis/bronchiolitis after Day 100 was 41% in the No Early Rejection Group and was 50% in the Early Rejection Group (p=0.17).
CONCLUSION: Surveillance bronchoscopy detects occult acute rejection or lymphocytic bronchitis/bronchiolitis in approximately one-third of biopsy specimens during the 1st year, with the majority of late abnormalities being minimal (A1) rejection. The absence of acute rejection or lymphocytic bronchitis/bronchiolitis during the first 100 days does not predict freedom from such events in the remainder of the 1st year.

Entities:  

Mesh:

Year:  2004        PMID: 15607670     DOI: 10.1016/j.healun.2003.09.018

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  7 in total

1.  Spirometrically significant acute rejection increases the risk for BOS and death after lung transplantation.

Authors:  W A Davis; C A Finlen Copeland; J L Todd; L D Snyder; J A Martissa; S M Palmer
Journal:  Am J Transplant       Date:  2011-11-28       Impact factor: 8.086

Review 2.  Heart-lung transplantation: pediatric indications and outcomes.

Authors:  Jonathan E Spahr; Shawn C West
Journal:  J Thorac Dis       Date:  2014-08       Impact factor: 2.895

3.  Usefulness of a preoperative inflammatory marker as a predictor of asymptomatic acute rejection after lung transplantation: a Japanese single-institution study.

Authors:  Takashi Kanou; Masato Minami; Naoki Wada; Soichiro Funaki; Naoko Ose; Eriko Fukui; Yasushi Shintani
Journal:  J Thorac Dis       Date:  2020-09       Impact factor: 2.895

Review 4.  Acute rejection and humoral sensitization in lung transplant recipients.

Authors:  Tereza Martinu; Dong-Feng Chen; Scott M Palmer
Journal:  Proc Am Thorac Soc       Date:  2009-01-15

Review 5.  Challenges in pulmonary fibrosis. 2: Bronchiolocentric fibrosis.

Authors:  Jean-François Cordier
Journal:  Thorax       Date:  2007-07       Impact factor: 9.139

6.  Acute allograft rejection: cellular and humoral processes.

Authors:  Tereza Martinu; Elizabeth N Pavlisko; Dong-Feng Chen; Scott M Palmer
Journal:  Clin Chest Med       Date:  2011-03-25       Impact factor: 2.878

Review 7.  Surveillance for acute cellular rejection after lung transplantation.

Authors:  Mark Greer; Christopher Werlein; Danny Jonigk
Journal:  Ann Transl Med       Date:  2020-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.